Clinical Aspect of Cytokines and Chemokines in Liver Transplant

Transplant Proc. 2022 Apr;54(3):755-761. doi: 10.1016/j.transproceed.2022.02.002. Epub 2022 Mar 7.

Abstract

Background: The objective of this prospective observational study was to determine whether a transplanted liver graft releases proinflammatory cytokines and chemokines on reperfusion and to determine the relationship between these molecules and subsequent ischemic reperfusion injury and acute kidney injury.

Methods: Blood samples from 66 consecutive patients undergoing liver transplant were analyzed for cyto- and chemokines at different time frames before and after liver transplant. Ischemic reperfusion injury was defined based on the peak levels of arginine transaminase and divided into 3 groups: mild, moderate, and severe. Acute kidney injury was defined according to the latest Kidney Disease: Improving Global Outcomes classification.

Results: For more than 40 different cyto/chemokines and growth factors, a certain pattern of expression was observed in all patients with ischemic reperfusion injury. G-SCF, IP10, and HSP90a were significantly elevated in all patients with ischemic reperfusion injury. On the other hand, eotaxin and MCP1 levels were markedly elevated in patients without ischemic reperfusion, suggesting a possible cytoprotective effect. We identified cold ischemia, macrosteatosis > 30%, postreperfusion syndrome, and postoperative use of 2 or more vasoactive agents as independent risk factors for ischemic reperfusion injury.

Conclusions: Ischemia reperfusion injury is accompanied by distinct innate and adaptive immune cytokine signatures before and after transplant. It can be used for therapeutic intervention with goal to improve post-transplant graft outcomes.

Publication types

  • Observational Study

MeSH terms

  • Acute Kidney Injury* / complications
  • Chemokines
  • Cytokines
  • Humans
  • Liver
  • Liver Transplantation* / adverse effects
  • Reperfusion Injury* / etiology

Substances

  • Chemokines
  • Cytokines